



POSTER PRESENTATION

Open Access

# Potency of an HIV-SAM<sup>TM</sup> vaccine in a heterologous prime-boost vaccination regimen

K Banerjee\*, Y Cu, Y Sun, K Hartog, A Dey, L Brito, A Verma, A Nandi, P Sarkar, NM Valiante, AJ Geall, SW Barnett, GR Otten

From AIDS Vaccine 2012  
Boston, MA, USA. 9-12 September 2012

## Background

Recombinant alphavirus replicon particles (VRP), carrying self-amplifying RNA, protects rhesus macaques against SHIVSF162P4 challenge when used in prime-boost regimen.

## Methods

Novartis has developed a synthetic self-amplifying mRNA (SAM<sup>TM</sup>) vaccine platform that avoids limitations of cell culture production and employs synthetic non-viral vaccine delivery systems.

## Results

We evaluated systemic and mucosal immune responses in mice and rabbits using the SAM<sup>TM</sup> platform expressing HIV-1 gp140 (HIV-SAM<sup>TM</sup> vaccine) prime, protein/MF59 vaccine boost regimen for both HIV-1 Clade B and C Env antigens. In mice, the primed Env-specific IgG response to 1 µg of the HIV-SAM<sup>TM</sup> vaccine was comparable to a 10 µg dose of an identically formulated DNA vaccine, 10(7) IU of VRP, and 10 µg protein/MF59 vaccines. The HIV-SAM<sup>TM</sup> vaccine primed response could be boosted robustly by a protein/MF59 vaccine and resulted in a balanced IgG1, IgG2a subclass response, similar to that seen with the VRP vaccine, but unlike the dominant IgG1 response to protein/MF59 only vaccinations. Both Env-specific CD4+ and CD8+ T-cell responses were detectable after two HIV-SAM<sup>TM</sup> vaccinations. A TH1 type (IFNγ+, IL-5-) profile was demonstrable for the HIV-SAM<sup>TM</sup> vaccine primed, protein boosted CD4+ T-cell response, similar to that seen with the DNA or VRP primed protein boosted responses, in contrast to a TH2 type (IFNγlow, IL-5+) response seen with protein/MF59 vaccination. In rabbits, priming with the 25 or 50 µg of the formulated

HIV-SAM<sup>TM</sup> vaccine induced robust and avid Env-binding IgG and HIV neutralizing antibodies that were superior to 500 µg of an unformulated DNA vaccine and comparable to VRP and protein/MF59 vaccines. In addition, protein/MF59 boostable Env-specific vaginal wash Ig was consistently demonstrable in both mice and rabbits immunized with the HIV-SAM<sup>TM</sup>.

## Conclusion

Together, these results suggest that HIV-SAM<sup>TM</sup> vaccine is potent and versatile and offers potential as a novel immune priming strategy. NIAID-NIH Grant 5P01AI066287.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P312

Cite this article as: Banerjee et al.: Potency of an HIV-SAM<sup>TM</sup> vaccine in a heterologous prime-boost vaccination regimen. *Retrovirology* 2012 **9** (Suppl 2):P312.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



Novartis Vaccines and Diagnostics, Cambridge, MA, USA



© 2012 Banerjee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.